research use only
Cat.No.S8749
| Related Targets | CDK HSP PD-1/PD-L1 ROCK Wee1 DNA/RNA Synthesis Microtubule Associated Ras KRas Aurora Kinase |
|---|---|
| Other Rho Inhibitors | NSC 23766 Trihydrochloride CCG-1423 EHop-016 ML141 (CID-2950007) EHT 1864 2HCl ZCL278 CCG-203971 CID44216842 1A-116 Rhosin hydrochloride |
|
In vitro |
DMSO
: 68 mg/mL
(200.93 mM)
Ethanol : 14 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 338.41 | Formula | C22H18N4 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 2097938-73-1 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CCN1C2=C(C=C(C=C2)N3C(=CN=N3)C4=CC=CC=C4)C5=CC=CC=C51 | ||
| Targets/IC50/Ki |
cdc42
(in metastatic breast cancer cells) 78 nM
Rac
(in metastatic breast cancer cells) 103 nM
|
|---|---|
| In vitro |
MBQ-167 inhibits mammary tumor growth and metastasis in immunocompromised mice by ~90%. |
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06075810 | Recruiting | Breast Cancer|Breast Neoplasm|Breast Cancer Stage IV |
MBQ Pharma|Congressionally Directed Medical Research Programs |
November 9 2023 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.